참고문헌
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. https://doi.org/10.3322/canjclin.55.2.74
- Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917. https://doi.org/10.1016/S0140-6736(03)14964-1
- Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236. https://doi.org/10.1002/hep.20933
- Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390. https://doi.org/10.1056/NEJMoa0708857
- Cheng AL, Guan Z, Chen Z, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer 2012;48:1452-1465. https://doi.org/10.1016/j.ejca.2011.12.006
- Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34. https://doi.org/10.1016/S1470-2045(08)70285-7
- Ganeshan A, Upponi S, Hon LQ, Warakaulle D, Uberoi R. Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology. Ann Oncol 2008;19:847-851. https://doi.org/10.1093/annonc/mdm528
- Sangro B, Inarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol 2012;56:464-473.
- Choi GH, Shim JH, Kim MJ, et al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology 2013;269:603-611. https://doi.org/10.1148/radiol.13130150
- Yoon SM, Lim YS, Won HJ, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys 2012;82:2004-2011. https://doi.org/10.1016/j.ijrobp.2011.03.019
- Kudo M. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. Dig Dis 2011;29:289-302. https://doi.org/10.1159/000327562
- Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-3140. https://doi.org/10.1158/1535-7163.MCT-08-0013
- Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-474. https://doi.org/10.1007/s12072-010-9165-7
- Lee HC. Systemic chemotherapy of hepatocellular carcinoma: Korean experience. Oncology 2008;75 Suppl 1:114-118. https://doi.org/10.1159/000173432
- Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008;99:159-165.
- Kim HY, Kim JD, Bae SH, et al. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. Korean J Hepatol 2010;16:355-361. https://doi.org/10.3350/kjhep.2010.16.4.355
- Ishikawa T, Imai M, Kamimura H, et al. Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. World J Gastroenterol 2007;13:5465-5470. https://doi.org/10.3748/wjg.v13.i41.5465
- Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 2008;38:474-483. https://doi.org/10.1111/j.1872-034X.2008.00338.x
- Nagano H. Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon. Oncology 2010;78 Suppl 1:142-147. https://doi.org/10.1159/000315243
- Yamasaki T, Sakaida I. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma and future treatments for the poor responders. Hepatol Res 2012;42:340-348. https://doi.org/10.1111/j.1872-034X.2011.00938.x
- Nishiyama M, Yamamoto W, Park JS, et al. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 1999;5:2620-2628.
- Kim BK, Park JY, Choi HJ, et al. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2011;137:659-667. https://doi.org/10.1007/s00432-010-0917-5
- Itamoto T, Nakahara H, Tashiro H, et al. Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol 2002;80:143-148. https://doi.org/10.1002/jso.10116
- Murata K, Shiraki K, Kawakita T, et al. Low-dose chemotherapy of cisplatin and 5-f luorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma. Anticancer Res 2003;23(2C):1719-1722.
- Woo HY, Bae SH, Park JY, et al. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2010;65:373-382. https://doi.org/10.1007/s00280-009-1126-2
- Strigari L, Sciuto R, Rea S, et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med 2010;51:1377-1385. https://doi.org/10.2967/jnumed.110.075861
- Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 1997;24:293-298.
- Kao YH, Tan EH, Ng CE, Goh SW. Clinical implications of the body surface area method versus partition model dosimetry for yttrium-90 radioembolization using resin microspheres: a technical review. Ann Nucl Med 2011;25:455-461. https://doi.org/10.1007/s12149-011-0499-6
- Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007;68:13-23. https://doi.org/10.1016/j.ijrobp.2006.11.060
- Wang SC, Bester L, Burnes JP, et al. Clinical care and technical recommendations for 90yttrium microsphere treatment of liver cancer. J Med Imaging Radiat Oncol 2010;54:178-187. https://doi.org/10.1111/j.1754-9485.2010.02167.x
- Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47:71-81.
- Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013;57:1826-1837. https://doi.org/10.1002/hep.26014
- Kim DY, Park BJ, Kim YH, et al. Radioembolization with Yttrium-90 resin microspheres in hepatocellular carcinoma: a multicenter prospective study. Am J Clin Oncol 2013 Sep 21 [Epub]. http://dx.doi.org/10.1097/COC.0b013e3182a78dba.
- Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium- 90 microspheres: a comprehensive report of longterm outcomes. Gastroenterology 2010;138:52-64. https://doi.org/10.1053/j.gastro.2009.09.006
- Cabibbo G, Latteri F, Antonucci M, Craxi A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol 2009;6:159-169. https://doi.org/10.1038/ncpgasthep1357
- Liao XF, Yi JL, Li XR, Deng W, Yang ZF, Tian G. Angiogenesis in rabbit hepatic tumor after transcatheter arterial embolization. World J Gastroenterol 2004;10:1885-1889. https://doi.org/10.3748/wjg.v10.i13.1885
- Shim JH, Park JW, Kim JH, et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 2008;99:2037-2044.
- Seong J, Park HC, Han KH, et al. Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. Hepatol Res 2003;27:30-35. https://doi.org/10.1016/S1386-6346(03)00162-1
- Park MS, Kim SU, Park JY, et al. Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. Cancer Chemother Pharmacol 2013;71:165-173. https://doi.org/10.1007/s00280-012-1993-9
- Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 1965;93:200-208.
- Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995;31:1237-1248. https://doi.org/10.1016/0360-3016(94)00418-K
- Lee IJ, Seong J. Radiotherapeutic strategies in the management of hepatocellular carcinoma. Oncology 2011;81 Suppl 1:123-133. https://doi.org/10.1159/000333275
피인용 문헌
- Ethyl acetate extract from Jiedu Xiaozheng Yin inhibits the proliferation of human hepatocellular carcinoma cells by suppressing polycomb gene product Bmi1 and Wnt/β-catenin signaling vol.32, pp.6, 2014, https://doi.org/10.3892/or.2014.3541
- Cavitary Form of Lung Metastasis from Advanced Hepatocellular Carcinoma vol.88, pp.2, 2014, https://doi.org/10.3904/kjm.2015.88.2.202
- Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma vol.21, pp.13, 2014, https://doi.org/10.3748/wjg.v21.i13.3843
- Subtractive Cell-SELEX Selection of DNA Aptamers Binding Specifically and Selectively to Hepatocellular Carcinoma Cells with High Metastatic Potential vol.2016, pp.None, 2014, https://doi.org/10.1155/2016/5735869
- Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways vol.7, pp.24, 2016, https://doi.org/10.18632/oncotarget.9168
- The effect and mechanism of bufalin on regulating hepatocellular carcinoma cell invasion and metastasis via Wnt/β-catenin signaling pathway vol.48, pp.1, 2014, https://doi.org/10.3892/ijo.2015.3250
- Anaplastic lymphoma kinase protein expression predicts micrometastases and prognosis for patients with hepatocellular carcinoma vol.11, pp.1, 2014, https://doi.org/10.3892/ol.2015.3859
- Investigation of quercetin‐induced HepG2 cell apoptosis‐associated cellular biophysical alterations by atomic force microscopy vol.38, pp.2, 2016, https://doi.org/10.1002/sca.21245
- Endocan silencing induces programmed cell death in hepatocarcinoma vol.14, pp.5, 2014, https://doi.org/10.3892/ol.2017.6857
- Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance vol.77, pp.3, 2014, https://doi.org/10.1080/00365513.2017.1286684
- Hepatocellular Carcinoma: Implications for Asia-Pacific Oncology Nurses vol.4, pp.2, 2017, https://doi.org/10.4103/2347-5625.204497
- Screening and function analysis of hub genes and pathways in hepatocellular carcinoma via bioinformatics approaches vol.22, pp.3, 2014, https://doi.org/10.3233/cbm-171160
- Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma : A STROBE-compliant article vol.97, pp.17, 2014, https://doi.org/10.1097/md.0000000000010611
- Inhibition of anaplastic lymphoma kinase promotes apoptosis and suppresses proliferation in human hepatocellular carcinoma vol.29, pp.6, 2018, https://doi.org/10.1097/cad.0000000000000616
- Autophagy in Hepatocellular Carcinoma-29 after Single or Combined Administration of Lithium Carbonate and Rapamycin vol.13, pp.5, 2014, https://doi.org/10.1134/s1990519x19050079
- Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis vol.64, pp.12, 2014, https://doi.org/10.1007/s10620-019-05701-8
- Value of surgical resection compared to transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein tumor thrombus: A meta-analysis of hazard ratios from five observa vol.24, pp.3, 2020, https://doi.org/10.14701/ahbps.2020.24.3.243
- CC Chemokine Ligand 17 Promoted Cell Metastasis via Tumor Necrosis Factorα/Nuclear Factor Kappa-B Signaling Pathway vol.11, pp.2, 2014, https://doi.org/10.1166/jbt.2021.2540